Thrombolysis, time-to-treatment and in-hospital outcomes among young adults with ischaemic stroke in China: findings from a nationwide registry study in China.
Aged
Brain Ischemia
/ drug therapy
Fibrinolytic Agents
/ therapeutic use
Hospitals
Humans
Ischemic Stroke
/ drug therapy
Middle Aged
Registries
Retrospective Studies
Stroke
/ drug therapy
Thrombolytic Therapy
Time-to-Treatment
Tissue Plasminogen Activator
/ therapeutic use
Treatment Outcome
Young Adult
adult neurology
stroke
vascular medicine
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
24 06 2022
24 06 2022
Historique:
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
We aimed to determine whether young adults (<50 years) with acute ischaemic stroke (AIS) are more likely to receive intravenous tissue plasminogen activator (IV tPA) and have shorter time to treatment than older patients with stroke. We analysed data from the Chinese Stroke Center Alliance registry for patients with AIS hospitalised between August 2015 and July 2019. Patients were classified into two groups according to age: young adults (<50 years of age) and older adults (≥50 years of age). Of 793 175 patients with AIS admitted to 1471 hospitals, 9.1% (71 860) were young adults. Compared with older adults, a higher proportion of young adults received IV tPA among patients without contraindicaitons (7.2% vs 6.1%, adjusted OR (aOR) 1.13, 95% CI 1.10 to 1.17) and among patients without contraindications and with onset-to-door time ≤3.5 hours (23.6% vs 19.3%, aOR 1.20, 95% CI 1.15 to 1.24). We did not observe differences in onset-to-needle time (median hours 2.7 hours) or door-to-needle time (DNT) (median minutes 60 min) between young and older adults. The proportion of DNT ≤30 min, DNT ≤45 min and DNT ≤60 min in young and older IV tPA-treated patients were 16.9% vs 18.8%, 30.2% vs 32.8% and 50.2% vs 54.2%, respectively. Compared with older adults, young adults treated with IV tPA had lower odds of in-hospital mortality (0.5% vs 1.3%, aOR 0.54, 95% CI 0.35 to 0.82) and higher odds of independent ambulation at discharge (61.0% vs 53.6%, aOR 1.15, 95% CI 1.08 to 1.22), and the associations may be partly explained by stroke severity measured by the National Institutes of Health Stroke Scale score. Young adults with AIS were more likely to receive IV tPA than older adults, although there was no difference between the two groups in time to treatment. Compared with older adults, young adults may had better in-hospital outcomes.
Sections du résumé
BACKGROUND AND PURPOSE
We aimed to determine whether young adults (<50 years) with acute ischaemic stroke (AIS) are more likely to receive intravenous tissue plasminogen activator (IV tPA) and have shorter time to treatment than older patients with stroke.
METHODS
We analysed data from the Chinese Stroke Center Alliance registry for patients with AIS hospitalised between August 2015 and July 2019. Patients were classified into two groups according to age: young adults (<50 years of age) and older adults (≥50 years of age).
RESULTS
Of 793 175 patients with AIS admitted to 1471 hospitals, 9.1% (71 860) were young adults. Compared with older adults, a higher proportion of young adults received IV tPA among patients without contraindicaitons (7.2% vs 6.1%, adjusted OR (aOR) 1.13, 95% CI 1.10 to 1.17) and among patients without contraindications and with onset-to-door time ≤3.5 hours (23.6% vs 19.3%, aOR 1.20, 95% CI 1.15 to 1.24). We did not observe differences in onset-to-needle time (median hours 2.7 hours) or door-to-needle time (DNT) (median minutes 60 min) between young and older adults. The proportion of DNT ≤30 min, DNT ≤45 min and DNT ≤60 min in young and older IV tPA-treated patients were 16.9% vs 18.8%, 30.2% vs 32.8% and 50.2% vs 54.2%, respectively. Compared with older adults, young adults treated with IV tPA had lower odds of in-hospital mortality (0.5% vs 1.3%, aOR 0.54, 95% CI 0.35 to 0.82) and higher odds of independent ambulation at discharge (61.0% vs 53.6%, aOR 1.15, 95% CI 1.08 to 1.22), and the associations may be partly explained by stroke severity measured by the National Institutes of Health Stroke Scale score.
CONCLUSION
Young adults with AIS were more likely to receive IV tPA than older adults, although there was no difference between the two groups in time to treatment. Compared with older adults, young adults may had better in-hospital outcomes.
Identifiants
pubmed: 35750455
pii: bmjopen-2021-055055
doi: 10.1136/bmjopen-2021-055055
pmc: PMC9234794
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e055055Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMC Neurol. 2011 Sep 20;11:109
pubmed: 21933424
Curr Neurol Neurosci Rep. 2019 Nov 25;19(11):91
pubmed: 31768660
Eur Stroke J. 2021 Mar;6(1):I-LXII
pubmed: 33817340
Stroke Vasc Neurol. 2020 Sep;5(3):211-239
pubmed: 32826385
Neth J Med. 2010 Mar;68(3):123-7
pubmed: 20308707
Neurology. 2019 Jun 11;92(24):e2784-e2792
pubmed: 31092622
Lancet Neurol. 2016 Aug;15(9):913-924
pubmed: 27291521
J Formos Med Assoc. 2014 Dec;113(12):929-33
pubmed: 24412584
Neurology. 2013 Sep 17;81(12):1089-97
pubmed: 23946297
Neurology. 2019 Jun 11;92(24):1129-1130
pubmed: 31092623
Neurology. 2012 Mar 20;78(12):880-7
pubmed: 22402853
Stroke. 2013 Apr;44(4):1080-4
pubmed: 23444310
Intern Med. 2012;51(20):2887-92
pubmed: 23064562
Circulation. 2004 Aug 3;110(5):588-636
pubmed: 15289388
Cerebrovasc Dis. 2007;24 Suppl 1:143-52
pubmed: 17971650
Stroke Vasc Neurol. 2018 Sep 8;3(4):256-262
pubmed: 30637133
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
JAMA. 2000 Jun 14;283(22):2941-7
pubmed: 10865271
Stroke. 2019 Nov;50(11):3228-3237
pubmed: 31526124
Ann Transl Med. 2018 Aug;6(16):326
pubmed: 30364007
Curr Neurovasc Res. 2017;14(2):141-148
pubmed: 28356003
Can J Neurol Sci. 2009 Mar;36(2):161-7
pubmed: 19378708
Curr Neurovasc Res. 2007 Aug;4(3):216-27
pubmed: 17691975
Am Heart J. 2005 Sep;150(3):583-7
pubmed: 16169345
J Neurol. 2008 Oct;255(10):1503-7
pubmed: 18677634
Nat Rev Neurol. 2014 Jun;10(6):315-25
pubmed: 24776923
Presse Med. 2016 Dec;45(12 Pt 2):e391-e398
pubmed: 27816343
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Stroke. 2020 Mar;51(3):729-735
pubmed: 32078487